Literature DB >> 16552180

Vascular integration of endothelial progenitors during multistep tumor progression.

Günter J Hämmerling1, Ruth Ganss.   

Abstract

Bone marrow-derived endothelial precursor cells contribute to tumor neovascularization. However, it is unclear when during progressive tumor growth circulating precursors are recruited into the preexisting vascular network, and how they home specifically into the tumor microenvironment. Here, we summarize recent findings from mouse models of multistage carcinogenesis, which reveal distinct phases of angiogenic activity. Only advanced tumors with a highly heterogeneous, sprouting vasculature recruite endothelial progenitors into neovessels. Surprisingly, during progressive tumor growth endothelial cells acquire new characteristics and secrete CC chemokines, a group of chemoattractants with adjacent cysteins, which play a dual role by enhancing neovascularization in an autocrine and endocrine fashion. Locally, chemokines stimulate endothelial proliferation; systemically, they guide chemokine receptor-positive circulating progenitors into the tumor bed. Subsequently, endothelial progenitors are truly integrated into the network of pre-existing vessels. This mechanism represents a novel concept where not the tumor itself, but endothelial cells as components of the tumor-induced stroma foster neovascularization in a self-amplifying loop.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552180     DOI: 10.4161/cc.5.5.2517

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  7 in total

1.  Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro.

Authors:  Yongfeng Fan; Jianqin Ye; Fanxia Shen; Yiqian Zhu; Yerem Yeghiazarians; Wei Zhu; Yongmei Chen; Michael T Lawton; William L Young; Guo-Yuan Yang
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-16       Impact factor: 6.200

Review 2.  Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment.

Authors:  Sophia Ran; Lisa Volk-Draper
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Y-box binding protein 1 expression in gastric cancer subtypes and association with cancer neovasculature.

Authors:  Y Wu; K-Y Wang; Z Li; Y-P Liu; H Izumi; S Yamada; H Uramoto; Y Nakayama; K Ito; K Kohno
Journal:  Clin Transl Oncol       Date:  2014-07-31       Impact factor: 3.405

4.  Chemically-induced cancers do not originate from bone marrow-derived cells.

Authors:  Hui Lin; Liang Hu; Leilei Chen; Hong Yu; Qi Wang; Ping Chen; Xiao-Tong Hu; Xiu-Jun Cai; Xin-Yuan Guan
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

5.  Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin.

Authors:  Damien Destouches; Diala El Khoury; Yamina Hamma-Kourbali; Bernard Krust; Patricia Albanese; Panagiotis Katsoris; Gilles Guichard; Jean Paul Briand; José Courty; Ara G Hovanessian
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

Review 6.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.

Authors:  M Mimeault; R Hauke; P P Mehta; S K Batra
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

7.  Identification of serum regression signs in infantile hemangioma.

Authors:  Daniela D'Arcangelo; Ezio M Nicodemi; Stefania Rossi; Claudia Giampietri; Francesco Facchiano; Antonio Facchiano
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.